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Abstract 
Introduction: Locally implanted antibiotic-eluting carriers may be a valuable adjuvant to the 
management of prosthetic joint infections. Aim: to assess local and plasma antibiotic concentrations 
as well as cumulative antibiotic urine excretion associated with clinical use of a gentamicin - or 
vancomycin-loaded mineral composite antibiotic carrier. 
Methods: 32 patients (male/female=19/13, mean age=56; 21-82 years) were prospectively followed 
after implantation of gentamicin (n=11), vancomycin (n=15), or a combination (n=7), using an 
antibiotic carrier (CERAMENT™|G or CERAMENT™|V, mean amount 11 (3-20) mL) during 
resection arthroplasty of the hip/knee. We measured antibiotic concentrations in plasma (1h, 3h, 
24h, 48h and 72h post-implantation), urine (24h, 48h and 72h post-implantation) and in drain (n=15).  
Results: We observed low antibiotic concentrations in plasma (Gentamicin: 0.33 mg/L (95%-CI: 
0.25-0.44) and vancomycin: 1.33 mg/L (95%-CI: 1.02-1.66)) and high concentrations in drain 
(Gentamicin: mean 57.8 mg/L (95%-CI: 45.8-69.7) and vancomycin: mean 234.4 mg/L (95%-CI: 
198.9-269.7)). Use of a drain was associated with a statistically significant reduction in vancomycin 
urine excretion (55.6% (95% CI: 36.45-74.92) to 28.71% (95% CI: 13.07-44.35), p=0.042). A similar 
trend was observed for gentamicin (34.17% (95% CI: 24.62-43.72) to 16.22% (95% CI: 0-33.86), 
p=0.078).  
Conclusions: CERAMENT™G/V was associated with safe plasma concentrations and high local 
concentrations above minimum inhibitory concentration. Installation of a surgical drain results in 
removal of a substantial amount of antibiotics and reduces antibiotic urine excretion. 
Key words: Antibiotic Carrier, Antibiotic Elution, Pharmacokinetics, Prosthetic Joint Infection 
Introduction 
The clinical and economic burden of 
implant-associated infections is projected to rise 
significantly during the coming decades (1), and rates 
of PJI (prosthetic joint infections) are especially 
increasing in patients with bone tumours, due to 
improved overall survival (2, 3). Immunosuppression, 
generally reduced performance status, and poor 
physiological reserve make the treatment of PJI in this 
patient population extremely challenging and 
demanding. Prosthetic implants remain particularly 
susceptible to infection throughout a patient’s entire 
lifetime due to their role as a foreign body, leading to 
a persistent focal decrease in minimal infecting 








the implant surface results in significantly increased 
tolerance to antibiotics, and demands antibiotics in 
extremely high concentrations if eradication of the 
respective microorganisms is to be achieved (5). After 
systemic administration, antibiotics must overcome 
absorption, protein-binding, ionisation and tissue 
diffusion. The rate and extent of aminoglycosides and 
glycopeptides into bone after systemic administration 
has been reported as bone: serum concentrations of 
0.1 – 0.3. Accordingly, systemic administration of 
aminoglycosides and glycopeptides in the treatment 
of PJI may demand high serum concentrations (6). 
Furthermore, administrable amounts are limited by 
the risk of various toxic reactions (7). Local antibiotic 
delivery with an appropriate carrier can bypass these 
obstacles and achieve extremely high local 
concentrations of antibiotics, which are often 
necessary to eradicate or prevent PJI (8). Several 
methods for antibiotic delivery into an area of 
bone/prosthetic joint infection exist. The antibiotic 
carrier most frequently employed in clinical practice 
is PMMA: polymethyl-methacrylate, applied as 
beads, rods or spacers, and successful results have 
been reported for treatment of both osteomyelitis and 
PJI (9, 10). However, since PMMA is not 
biodegradable and continues to release antibiotics at 
low concentrations for many years, its use is 
associated with a need for secondary surgery (for 
removal of the PMMA), development of bacterial 
resistance, and possible re-colonisation (8, 11, 12). 
There is an increasing role for alternative 
antibiotic-eluting carriers that are isothermic, provide 
high local concentrations of antibiotics (as well as 
sufficiently low corresponding plasma levels to avoid 
toxic damage), and are fully biodegradable to avoid 
bacterial resistance and re-colonisation. Until now, the 
concept of locally implanted antibiotics for 
biofilm-associated infections has been mostly studied 
in in-vitro models. However, their resemblance to 
in-vivo models and their clinical relevance are being 
questioned (13). In order to improve the 
understanding of the possible role of local antibiotic 
delivery in the treatment of chronic PJI, clinical data is 
imperative. The purpose of this study was to 
investigate clinical in-vivo antibiotic elution 
characteristics and pharmacokinetic properties of a 
commercially available antibiotic eluting BGS: Bone 
graft substitute that has shown promising in-vitro and 
in-vivo results in the treatment or prevention of bone 
and joint-infections (8, 11, 14). In particular, we 
studied the local antibiotic concentrations achieved 
in-situ, the maximum antibiotic serum concentrations, 
and cumulative antibiotic excretion in urine over the 
first three post-operative days. An aminoglycoside 
(gentamicin) and/or a glycopeptide (vancomycin) 
were applied in a commercially available 
antibiotic-eluting BGS (bone graft substitute), for 
prevention or treatment of PJI. Gentamicin is a 
bacteriocidic agent that attacks both the ribosome and 
cell wall of the primarily gram-negative rod in aerobic 
conditions. Vancomycin attacks gram-positive cell 
walls, thereby working bactericidically (15). This is 
the first clinical study that investigates the in-vivo 
elution profile of this antibiotic carrier in plasma, 
drain-fluid and urine in a cohort of patients.  
Methods 
We prospectively evaluated 32 patients (M: F = 
19:13, mean age = 56 (range 21-82) years), who 
underwent local implantation of a commercially 
available antibiotic-eluting BGS for prevention or 
treatment of PJI in our department between February 
2016 and February 2017. 12 of cases were treated with 
therapeutic intent, with either DAIR (debridement, 
antibiotic and implant retention), or 1-stage or 2-stage 
revision for an acute or chronic PJI. 20 cases were 
treated with prophylactic intent during primary or 
revision implantation of a mega-implant, after either 
extensive primary bone tumour resection or revision 
of a loose and/or failed revision hip or knee 
arthroplasty (Table 1). The BGS utilised 
(CERAMENT™, Bonesupport AB Lund, Sweden), is a 
bio-composite of calcium sulphate and 
hydroxyapatite, containing either 17.5mg/mL of 
gentamicin (CERAMENT™|G) or 66mg/mL of 
vancomycin (CERAMENT™|V), which forms an 
injectable, rapidly hardening paste. The 
antibiotic-loaded BGS was either applied directly onto 
the surface of the endoprosthetic implants as a paste, 
injected into periprosthetic bone defects, or deposited 
in immediate proximity of the exposed bone and/or 
endoprosthetic components as hardened beads/rods. 
CERAMENT™|G was implanted in 11 cases (mean 
volume 12.1mL (range: 3-20mL)), CERAMENT™|V 
in 15 cases (mean volume 11.1mL (range: 5-20mL)) 
and a combination of both products in the remaining 
7 cases (mean volume of 9.7mL (range 8-10mL) and 
10mL, respectively) (Table 1). The choice between 
CERAMENT™|G, CERAMENT™|V or a 
combination of the two was made in collaboration 
between the microbiologist and surgeon based on the 
previously identified profile of pathogens. We 
analysed drain fluid, serum, and urine sample 
concentrations of gentamicin and vancomycin to 
assess in-vivo elution characteristics and 
pharmacokinetic behaviour of these two antibiotics 
after release from the carrier. Patients receiving 
concomitant systemic gentamicin or vancomycin were 
not included in the study. Blood was collected after 
(A) 30 minutes, (B) 3 hours, (C) 24 hours, (D) 48 hours, 




and (E) 72 hours post-implantation. Samples were 
centrifuged at 3000 RPM: Rounds per minute, (1500G) 
for 10 minutes. The supernatant was transferred to a 
2mL polypropylene tube and placed in a bio-freezer at 
-80°C for subsequent antibiotic concentration 
measurements. In 15 patients, a deep surgical wound 
drain was applied. In these patients, total drain 
output volume was measured when the drain was 
removed after a mean of 90 hours (range: 48-144, 
removal criteria: <50mL drain fluid production over 
the previous 24h). Drain fluid was collected at a single 
point in time (when the drain was removed) to obtain 
data on the total cumulative loss of antibiotic through 
the surgical drain. Drain fluid was transferred to a 
5mL heparin tube, centrifuged at 3000RPM (1500G) 
for 10 minutes, and the supernatant transferred to a 
2mL polypropylene tube and placed in a bio-freezer at 
-80°C prior to concentration analysis. 24-hour urine 
output was collected over three days, counting from 
the time of antibiotic implantation (t=0). The volume 
was registered for each 24h urine container, and 
samples were taken separately and immediately 
transferred to a bio-freezer at -80°C in a 4mL 
polypropylene tube for subsequent antibiotic 
concentration analysis. Antibiotic concentrations were 
analysed using MULTIGEN; a PETINA (particle- 
enhanced turbid metric inhibition immunoassay) in 
all three media.  
Statistics and ethical approval 
We performed an unpaired t-test to compare the 
cumulative antibiotic urine output between patients 
with deep wound drain and no deep wound drain, 
respectively. P-values <0.05 were considered 
statistically significant. SPSS version 23 and SAS 
Enterprise 7.1 software were used for statistical 
assessments. Data is presented as mean and with 95% 
confidence intervals (95%CI). The study has been 
approved by the National Data Protection Agency 
(J.no.2013-41.2591) and regional ethics committee (J. 
no H-3-2014-133). All procedures were in accordance 
with the ethical standards of the responsible 
committee on human experimentation and with the 
Helsinki Declaration of 1975, as revised in 1983. 
Results 
We obtained an average cumulative drain output of 
698mL (range: 50-3500mL), which was collected over 
a mean of 90h (range: 48-144) post-antibiotic 
implantation (Table 2), with mean drain-fluid 
concentrations of 57.8 mg/L (95 % CI: 45.8-69.7) for 
gentamicin and 234.4 mg/L (95% CI: 198.9-269.7) for 
vancomycin, respectively. We found a mean plasma 
gentamicin concentration of 0.33 mg/L (95% CI: 
0.25-0.44) and a mean plasma vancomycin 
concentration of 1.33 mg/L (95% CI: 1.02-1.66). The 
in-vivo plasma concentration profile of gentamicin 
peaked very early after antibiotic implantation (3h 
post-op), followed by a fast and persistent drop 
during the remaining period of analysis, whereas the 
respective vancomycin plasma concentration profile 
peaked somewhat later (24h post-op) and tended to 
drop slower (figure. 1). The maximum individual 
concentration measured was 2.14 mg/L for 
gentamicin and 10.32 mg/L for vancomycin. A 
comparison to the trough toxic levels of gentamicin 
(2mg/L) and vancomycin (10 mg/L) (11, 16) is 
illustrated in figure. 2. We did not observe any 
alteration in the elution profile in cases where 
gentamicin and vancomycin were combined. 
 
Table 1. Treatment characteristics in 32 cases with locally implanted Gentamicin and/or Vancomycin in a commercially available antibiotic 
carrier (CERAMENT™) 
 Gentamicin Vancomycin Combined 
Gender (M:F) 7:4 7:7 5:2 
Indication & Procedure    
  Therapeutic (PJI) 3 6 3 
 DAIR  1 2 2 
 1-Stage  2 2 0 
 2-Stage  0 2 1 
  Prophylactic  8 8 4 
 Primary Tumour-prosthesis  7 4 3 
 Revision Arthroplasty 1 4 1 
    
Antibiotic Carrier  
mean volume (mL) and corresponding antibiotic 
concentration (mg). 
  CERAMENT™|G & CERAMENT™|V 
12.1 (3-20) 11.1 (5-20) 9.7 (8-10) 10 (10-10) 
211,75 (52,5-350) 732,6 (330-1320) 169,75 (140-175) 660 (660-660) 
 
 





Figure 1. Mean plasma-concentration of (A) gentamicin and (B) vancomycin during the first three days post antibiotic implant. Time points indicate 1, 3, 24, 48 and 
72 hours post-operatively. Error bars indicate standard error of mean. 
 
Table 2. Gentamicin and vancomycin concentrations in drain fluid, plasma and urine in 32 cases treated with a commercially available 
antibiotic carrier (CERAMENT™) 
 Gentamicin Vancomycin 
 Cases (n) Mean concentration (mg/L) 95% CI Cases (n) Mean Concentration (mg/L) 95% CI 
Drain 5 57.8 45.8-69.7 11 234.4 198.9-269.7 
Plasma (peak) 17 0.33 (2.14) 0.25-0.44 15 1.33 (10.32) 1.02-1.66 
Urine (No drain) 12 23.32 14.0-32.6 10 121.02 61.10-174.9 




Figure 2. Peak plasma-concentrations (highest measured antibiotic 
concentration) of gentamicin (blue) and vancomycin (green) during the first 
three days post antibiotic implant with the corresponding toxic trough levels. 
 
The mean percentage of locally implanted 
gentamicin, excreted in urine after 3 days, was 16.22% 
(95% CI: 0-33.86) and 34.17% (95% CI: 24.62-43.72) for 
cases with (n=5) or without (n=12) a surgical drain. 
100% refers to the total amount of implanted 
antibiotics. For vancomycin, the corresponding ratios 
were 28.71% (95% CI: 13.07-44.35) and 55.6% (95% CI: 
36.45-74.92) for patients with (n=11) or without (n=10) 
a surgical drain, indicating that the installation of a 
deep wound drain substantially decreases cumulative 
antibiotic urine excretion (table 2 presented as mg/L 
and figure 3 presented as cumulative percentages). In 
patients treated with local vancomycin, the observed 
difference in excretion was statistically significant 
(p=0.042). In patients treated with gentamicin, a 
similar tendency was observed but did not quite reach 
statistical significance (p=0.078).  
Discussion  
Drain fluid – local concentration  
Compared to the conventional minimally 
inhibitory concentrations (MIC) reported for 
planktonic pathogens typically involved in PJI (17, 
18), the drain fluid concentrations we found in our 
study were approximately 30-60 times higher for 
gentamicin and vancomycin, respectively. Local 
antibiotic concentrations at these levels have been 
shown to eradicate planktonic bacteria and prevent 
implant surface colonisation in-vitro (8), which may 
potentially translate to a risk reduction for PJI. It has 
been reported, however, that mature biofilm requires 
significantly higher threshold-levels and MBEC 
(minimal biofilm eradicating concentrations) - over 
1000 times greater than the corresponding MIC (18, 
19). Together with other researchers in a previous 
study investigating the same antibiotic carrier in-vivo, 




we found local gentamicin concentrations of up to 
2000 mg/L, indicating that antibiotic concentrations 
significantly above MBEC levels are achievable using 
the tested material as a local antibiotic carrier (11). 
Due to differences in study designs, we were unable 
to reproduce such high concentrations in our 
drain-fluid samples in this study. For reasons of 
simplicity, we used the antibiotic concentration in 
drain fluid as a surrogate measure of the in-vivo local 
concentration, because measurement of actual local 
antibiotic concentrations is difficult and not feasible 
without an additional intervention in-vivo in a clinical 
context. It is possible that actual local antibiotic 
concentrations and corresponding potential 
bacteria-eradicating ability, are higher in areas of 
proximity to, or within the antibiotic-loaded carrier or 
lower in more peripheral wound compartments at 
greater distance or even separated from the carrier. 
Additionally, although it can be considered an 
important supplement in the understanding of 
antibiotic effect, the antibiotic concentration analysed 
in a particular compartment is not a unique measure 
of the antibiotic activity and 
potential pathogen eradication. 
This measurement needs to be 
considered within the overall 
clinical scenario (17). To our 
knowledge, clinical results of local 
use of antibiotic-eluting BGS for 
PJI have, so far, only been 
published in case reports (20, 21). 
However, excellent clinical results 
have been reported in related 
scenarios of biofilm-associated 
bone and joint infections. McNally 
et. al. achieved eradication of 
infection in a cohort of 100 patients 
with chronic osteomyelitis, treated 
with a single-stage protocol and 
dead-space management with the 
same antibiotic carrier (14), and 
concluded that the surgical 
treatment facilitated by the 
antibiotic carrier was an effective 
and patient-friendly treatment of 
chronic osteomyelitis.  
Plasma – systemic toxicity  
It is well known that elevated 
systemic levels of gentamicin and 
vancomycin may cause toxic ear 
damage and renal failure, and 
antibiotic trough levels must 
therefore be carefully monitored 
to guide the dosage of the 
antibiotic to minimise the risk of complications. 
Trough toxic levels are estimated to be 2mg/L for 
gentamicin and 10 mg/L for vancomycin (11, 16). 
Accordingly, the plasma levels observed in this study 
were well below these levels and cannot be 
considered nephrotoxic or ototoxic. This finding 
agrees with other studies examining the same 
antibiotic carrier, confirming equally low plasma 
levels and/or no side-effects related to antibiotic 
toxicity (11, 22, 23). However, other studies report 
potential toxic antibiotic levels when using local 
antibiotic eluting grafts (24) and special caution must 
be taken when a patient is suffering with concomitant 
renal failure (25). A potential risk of antibiotic toxicity 
must, therefore, still not be neglected, particularly 
when using local antibiotics in extreme dosages, 
regardless of the carrier material through which they 
are applied. Finally, in order to compare this data 
appropriately with that reported on PMMA, in 
addition to serum plasma-concentration 
measurements, thorough clinical follow-up with 
regards to possible side-effects is required for up to 
 
Figure 3. Cumulative urine output of (A) gentamicin and (B) vancomycin. Blue bars indicate patients without 
a surgical drain and green bars indicate patients with a surgical drain. Error bars indicate standard error of 
mean. 
 




five years post-implantation, as reported in early 
PMMA in-vitro elution studies (12).  
Urine output – elution and excretion 
Measurement of antibiotic concentrations in 
urine is a simple and non-invasive method to 
indirectly monitor the elution from an antibiotic 
carrier in-vivo. A previous investigation of urine 
elution from various antibiotic carriers was able to 
trace gentamicin in urine for up to 95 days (10). The 
results observed in our study are comparable with a 
similar study that previously analysed urine sample 
concentrations after local implantation of the same 
antibiotic-loaded carrier (CERAMENT™|G) for 
another set of indications, and found the same overall 
urine excretion profile with detectable levels for up to 
7 days post-surgery (11). Neither of these two or any 
other previous studies, however, have investigated or 
quantified the effect of a deep drain on antibiotic 
urine output. In our study, pooled daily urine outputs 
were measured to study the potential amount of 
antibiotic absorbed from the implantation site and 
subsequently excreted in urine. Theoretically, 95% of 
vancomycin and 60-90% of gentamicin is excreted in 
the kidneys, unchanged when administered 
intravenously (15). However, since antibiotic 
absorption and elimination is dependent on the 
available amount of local antibiotic, our results clearly 
indicate that use of a deep drain that physically 
removes fluid, as well as antibiotics from the site of 
operation significantly affects the amount of antibiotic 
excreted in urine. Accordingly, it is likely that the 
amount of locally available antibiotic is equally 
reduced by one third to one half, which potentially 
compromises the desired antimicrobial effect of the 
locally implanted drug-eluting carrier. We therefore 
recommend avoiding use of deep surgical drains in 
conjunction with implantation of local antibiotic 
carriers, if possible. 
In conclusion, our study shows that local 
implantation of a commercially available gentamicin- 
and vancomycin-eluting BGS with the intention to 
prevent or treat PJI, is associated with high local 
concentrations, which by far exceed the MIC for most 
bacteria involved in prosthetic joint infections, and 
safe low plasma-concentrations for both antibiotics. 
Accordingly, CERAMENT™ might be a valuable 
addition to the treatment/prevention of PJI, however, 
use of a surgical drain may significantly reduce the 
amount of locally available antibiotic and should 
therefore be avoided if possible. Further clinical 
studies are needed to confirm whether this translates 
into a noticeable clinical effect. Based on our 
observations, antibiotic urine concentration 
measurements can be an effective, non-invasive 
method to monitor the in-vivo antibiotic elution from 
an antibiotic carrier in clinical practice. 
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